Home' Australian Pharmacist : Australian Pharmacist June 2014 Contents Australian Pharmacist June 2014 I ©Pharmaceutical Society of Australia Ltd.
Items in the Product news section are prepared from information provided by the companies named in each
item. They are included for the information of PSA members. It is up to the individual member to use their
professional judgment to decide on the merit or otherwise of each product mentioned. PSA neither endorses
nor confirms claims made in the items. (Where provided by the company references citing evidence are
included with the items.)
Australian Pharmacist is a professional journal. It will carry only advertising which is likely to be of interest to all
pharmacists and which does not reflect unfavourably directly or by implication on the pharmacy profession or
the professional practice of pharmacy. Advertising which does not comply with this policy will be refused. It is
the responsibility of the advertisers to comply with the relevant Commonwealth and State law. Advertising does
not constitute an endorsement by PSA of the claims, products or services.
Read in greater detail more regularly than any other pharmacy title –
such constant behaviour means you can count on our readers to open
any issue and be seen!
» Greatest number of recipients opening and reading (82%)
» Greatest number of readers reading every issue (48%)
Engage with almost 18,800 PSA members every month (15,500
pharmacists in print and 16,000 in digital form).
» Australian Pharmacist is read by 65% of community pharmacists
It has an extremely strong CPD program followed by more than 10,000
pharmacists – a typical monthly article receives 3000 plus assessments,
with highs over 4000!
» Greatest average proportion read (73%)
» Circulation 14,872 cab March 2013
TO ADVERTISE in the best-read pages in pharmacy media and give your campaign real
impact, and greater recognition, contact Tremain Media.
Ph: 02 9988 4689
Ph: 02 9547 3001
Ph: 02 9871 5520
*Competitive Advantage Research August 2012 – 632 practicing community pharmacists
An estimated 170,000 Australian adults
collectively living with two burdensome
forms of spondyloarthropathies may
benefit from the Therapeutic Goods
Administration (TGA) approval of
two new indications for a structurally
different anti-TNF treatment option.
Cimzia (certolizumab pegol) – the only
Fc-free, PEGylated anti-TNF – is now
indicated for the treatment of adults
with active Ankylosing Spondylitis (AS)
who have been intolerant to, or have
inadequate response to at least one
non-steroidal anti-inflammatory drug
(NSAID), and adults with active Psoriatic
Arthritis (PsA) where response to
previous DMARDs has been inadequate.
This means that more adults suffering
from rheumatic diseases, including
moderate to severe rheumatoid
arthritis (RA), AS and PsA, have another
treatment option available to them.
UCB Australia is working to make Cimzia
available on the Pharmaceutical Benefits
Scheme (PBS) to adults living with AS
Leading rheumatology expert,
Professor Matthew Brown, Institute
Director, The University of Queensland
Diamantina Institute, Brisbane, said
that certolizumab pegol offers both
physicians and patients flexible dosing
options, allowing treatment plans to
be adjusted to better suit individual
Cimzia has a proven, long-term efficacy
and safety profile of more than 13 years,
in 34,000 patients, across a number
of indications. A loading dose of
by maintenance dosing with either
every 4 weeks is recommended.
Bisolvon Chesty Forte
Liquid on-the-go Sachets
Boehringer Ingelheim has launched
Bisolvon Chesty Forte Liquid on-the-go
Sachets. This Pharmacy (S2) product
is on pharmacy shelves from 1 June.
Bisolvon Chesty Forte Liquid Sachets
provides the same double strength
formula in a convenient single dose,
ideal for work, school or travel.
It provides soothing relief from stubborn
chest congestion and is perfect for
on-the-go customers. The product
does not require a measuring cup as
each sachet contains a single dose of
8 mg bromhexine, the same strength as
Bisolvon Chesty Forte Liquid per 5 mL.
Sally Binfield, Senior Product Manager
at Boehringer Ingelheim said the
new product is part of the company’s
commitment to helping pharmacists
and pharmacy assistants better meet
the needs of their customers.
Bisolvon maintains its commitment to
pharmacy with a massive media spend
in 2014 including TV and online, and
introduces a new 15” TVC featuring the
new Sachets and top selling tablets.
Boehringer Ingelheim continues to
invest in consumer and trade marketing
in an effort to drive more customers into
community pharmacy this year.
Links Archive Australian Pharmacist May 2014 Australian Pharmacist July 2014 Navigation Previous Page Next Page